Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.41 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29184903 | 0.82 | ESR1 (0.46) | TSHRESR1ESR2 | |
| SCHEMBL28932553 | 0.76 | TSHR (0.60) | CYP3A4CYP19A1CYP17A1CYP11B1CYP11B2 | |
| SCHEMBL235417 | 0.75 | TSHR (0.58) | KDM4ETSHRLMNACYP2D6 | |
| SCHEMBL236726 | 0.75 | TSHR (0.58) | KDM4ETSHRLMNACYP2D6 | |
| SCHEMBL77244 | 0.75 | TSHR (0.58) | KDM4ETSHRLMNACYP2D6 | |
| SCHEMBL30708000 | 0.74 | SMN1; SMN2 (0.55) | CYP19A1CYP17A1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3211055 | 0.74 | SMN1; SMN2 (0.55) | CYP19A1CYP17A1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6962580 | 0.73 | ESR1 (0.62) | CYP3A4CYP19A1CYP17A1CYP11B1CYP11B2 | |
| SCHEMBL132554 | 0.71 | AOC3 (0.38) | HDAC8KDM4ETSHRESR1ESR2 | |
| SCHEMBL6957145 | 0.71 | MAPT (0.38) | CYP3A4CYP19A1KDM4EHSD17B10TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3891148-A1 | RET INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Sunshine Lake Pharma Co., Ltd. (CN) | 2021-10-13 | — | — | EP | disclosed |
| WO-2020114494-A1 | RET INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2020-06-11 | — | — | WO | disclosed |
| US-20140155381-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. | 2014-06-05 | — | — | US | disclosed |
| US-20140155381-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. | 2014-06-05 | — | — | US | disclosed |
| US-20140155381-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. | 2014-06-05 | — | — | US | disclosed |
| EP-2736332-A1 | COMPOUNDS AND METHODS | Tempero Pharmaceuticals, Inc. (US) | 2014-06-04 | — | — | EP | disclosed |
| WO-2013019653-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2013-02-07 | — | — | WO | disclosed |
| WO-2013019653-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2013-02-07 | — | — | WO | disclosed |
| US-20100298384-A1 | NOVEL OXAZOLIDINONE COMPOUNDS AS ANTIINFECTIVE AGENTS | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-11-25 | — | — | US | disclosed |
| WO-2008143649-A2 | NOVEL OXAZOLIDINONE COMPOUNDS AS ANTIINFECTIVE AGENTS | DR. REDDY'S LABORATORIES LIMITED (IN) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298384-A1 | NOVEL OXAZOLIDINONE COMPOUNDS AS ANTIINFECTIVE AGENTS | OXA1L, MIF, VIP | HDAC8 662/4885CYP3A4 836/4885CYP19A1 3781/4885 |
| US-20140155381-A1 | COMPOUNDS AND METHODS | RORC, RORB, RORA | HDAC8 422/4885CYP3A4 710/4885CYP19A1 410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.